Skip to main content
SpringerLink
Log in

Kontinuierliche subkutane Apomorphin-Gabe bei fortgeschrittener Parkinson-Krankheit

  • Literatur kompakt
  • Published:
DNP - Der Neurologe & Psychiater Aims and scope

In einer pivotalen Phase-III-Studie wurde die Wirksamkeit der kontinuierlichen subkutanen Gabe von Apomorphin bei Parkinson-Patienten mit persistierenden motorischen Wirkungsfluktuationen bewiesen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Kruger R, Klucken J, Weiss D et al. Classification of advanced stages of Parkinson’s disease: translation into stratified treatments. J Neural Transm (Vienna) 2017;124:1015–27

    Article  Google Scholar 

  2. Katzenschlager R, Poewe W, Rascol O et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018;17:749–59

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Lars Tönges

Authors
  1. Lars Tönges
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tönges, L. Kontinuierliche subkutane Apomorphin-Gabe bei fortgeschrittener Parkinson-Krankheit. DNP 20, 18–19 (2019). https://doi.org/10.1007/s15202-019-2135-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15202-019-2135-6

Search

Navigation